| REG UL ATI ON OF PD -LE XPRE SS I ON IN RE S P ON S E TO DNA DAMAG E S I G NALING IN C AN CER CELL S
Cancer therapies such as radiotherapy and chemotherapy cause cell death through DNA damage. Recent studies have suggested that the DNA damage response is an important factor influencing the efficacy of cancer immunotherapy. 1, 2 DNA damage induced by IR, etoposide, camptothecin, cisplatin, mitomycin C, and alkylating agents upregulates PD-L1 expression in cancer cells. 3 In this section, we describe the current state of knowledge of the molecular mechanisms underlying the regulation of PD-L1 expression in response to DSB induction and the influence of DSB repair and signaling.
A DSB is a critical form of DNA damage, and the capability to repair DSBs significantly influences cell fate. Among the available cancer treatments, IR, etoposide, and camptothecin therapy kills cancer cells by inducing DSBs. In human cells, DSBs are repaired by NHEJ or HR ( Figure 1 ). 4, 5 Immediately following the introduction of DSBs, cells emit a warning signal that arrests the cell cycle by activating a cell cycle checkpoint signal. 6 Double-strand break repair and cell cycle checkpoint arrest cooperate to facilitate the recovery of cells after DSBs. Following the induction of DSBs, ATM, which is the central DNA damage signal transducer, is rapidly and transiently activated at the DSB site. 7 Activation of ATM occurs predominantly at unresected DSB ends, including those undergoing NHEJ (Figure 1 ). 8 In contrast, ATR, the other central DNA damage signal transducer, is activated at DSB ends undergoing HR ( Figure 1 ). 8, 9 In the axis of cell cycle checkpoint activation, ATM activates Chk2 and p53, whereas ATR activates Chk1 (Figure 1 ). The ATM-ATR/Chk1-dependent phosphorylation signaling cascade activates further signal transduction, leading to cell cycle arrest. 6 P53 is frequently inactivated in cancer cells; therefore, the G 1 /S checkpoint is rarely effectively activated in cancer cells. In contrast, the G 2 /M checkpoint is activated with relative efficiency in cancer cells, which explains why such cells exposed to DNA-damaging agents frequently accumulate in G 2 phase. The ATR/Chk1 pathway mainly contributes to the arrest of cells in G 2 phase. 10 During HR, DSB ends are processed by DNA nucleases to generate 3′-overhangs (called "DSB end resection").
The process of DSB end resection is triggered by CtIP/MRE11-dependent endonuclease incision, which nicks the 5′ strand at DSB ends. Subsequently, the exonuclease activities of MRE11, exonuclease 1, and DNA2 expand resection by digesting DNA bidirectionally to produce a sufficient length of ssDNA. 5, 11 Following resection, the generated ssDNA is required for DNA strand invasion and D-loop formation. Additionally, ATR is activated by ssDNA coated with RPA, and the activation of the ATR/Chk1 pathway is, therefore, highly associated with the magnitude of DSB end resection ( Figure 1 ). 9, 12 As the ssDNA serves as a scaffold for ATR-mediated Chk1 activation, ATR/Chk1 is also activated at ssDNA gaps when DNA replication is stalled. 13 Several recent studies reported that DNA damage induces the expression of PD-L1 mRNA, which results in the increase in the cell surface expression of PD-L1. 3, [14] [15] [16] This process depends on the activity of the ATM-ATR/Chk1 signal transduction, suggesting that the expression of PD-L1 is controlled by DNA damage signaling. Thus, the activation of the ATM-ATR/Chk1 signal during the repair process above is a critical step leading to the upregulation of PD-L1 after exogenous genotoxic stress. In the next paragraph, we introduce the concept that there is greater upregulation of DSB-induced PD-L1 in a repair defective background.
F I G U R E 1 Orchestration of double-strand break (DSB) repair and its associated signaling activity. DSBs are repaired by non-homologous end joining (NHEJ) or homologous recombination (HR). NHEJ repairs DSBs throughout the cell cycle except for M phase in mammalian cells, whereas HR functions only in S/G 2 phase following DNA replication. DSB ends undergoing NHEJ, which are not resected, activate ataxiatelangiectasia mutated (ATM). In contrast, DSB ends that undergo resection by DNA nucleases promote HR. The Ku70/80 (Ku) and DNAdependent protein kinase catalytic subunit (DNA-PKcs) complex binds to most DSB ends to protect them from DNA nucleases and thereby promote NHEJ. In G 1 phase, an ATM/p53-dependent pathway activates G 1 /S checkpoint arrest, whereas in G 2 phase, ataxia telangiectasia and Rad3 related (ATR)/checkpoint kinase (Chk1) activates G 2 /M checkpoint arrest. As ATM is required for resection, ATM contributes to G 2 /M checkpoint arrest. RPA, replication protein A In our recent study, we found that depletion of Ku70/80 or BRCA2 significantly enhances the upregulation of PD-L1 expression after IR. 3 Ku70/80 and DNA-PKcs bind to most DNA break ends immediately after the induction of DSBs ( Figure 1 ). 11, 17 Among the multiple roles of DNA-PKcs in NHEJ, it aids the recruitment of NHEJ repair factors following its autophosphorylation. In addition to a role for Ku in recruiting DNA-PKcs and facilitating NHEJ, the role of immediate binding of Ku70/80 to the DSB ends has been considered to protect DSB ends from inappropriate DNA digestion by DNA nucleases. 18, 19 Consistent with this notion, depletion of Ku70/80 complexes enhances DSB end resection, which has been ascribed to the failure of DSB end protection, followed by increased ATR/Chk1 activation compared with that of control cells. Consistent with the increased activation of ATR/Chk1 signaling, depletion of Ku70/80 enhances further upregulation of the expression of DNA damage-dependent PD-L1. 3 Additionally, BRCA2 depletion also induces upregulation of PD-L1 expression after DSB formation. BRCA2 is required for HR by functioning to promote the switch from RPA to RAD51 on regions of ssDNA ( Figure 1 ). Therefore, BRCA2 depletion impairs the ability to switch from RPA to RAD51 and consequently RPA accumulates at DSB ends, which is associated with continuous activation of ATR/Chk1 signaling. Thus, increased upregulation of PD-L1 expression in BRCA2-depleted cells is considered to be caused by the continuous activation of ATR/Chk1 signaling.
Consistent with this idea, increased upregulation of PD-L1 expression in BRCA2-depleted cells is significantly suppressed by inhibition of ATR/Chk1 signaling. 3 However, because oxidative DNA damage does not directly introduce DSBs, we hypothesize that ATR/Chk1 signaling is activated after oxidative DNA damage through replication-associated DNA damage in S phase. 14 As ATR/Chk1 can be activated at single-strand gaps during the stalling of DNA replication, replication stress induced by oxidative stress could also be involved in the upregulation of PD-L1 irrespective of direct DSB induction.
As a downstream component of ATR/Chk1 signaling, STAT1/3-IRF1 play an important role in generating the signal that activates the transcription of PD-L1 mRNA. 3 Generally, in the context of the immune response, PD-L1 expression is controlled by STAT1/3 phosphorylation and IRF1 expression following the stimulation of IFNγ. 20, 21 Interferon regulatory factor 1 binds to the promoter region of PD-L1 to upregulate PD-L1 transcription. 21 Interestingly, we found that phosphorylation of STAT1/3 as well as IRF1 expression are induced by DNA damage. 3 Furthermore, the increase in IRF1 expression by DSBs is suppressed by a specific ATM inhibitor, suggesting that the ATM-ATR/Chk1 pathway is required for STAT1/3-IRF1-dependent PD-L1 expression ( Figure 2 ).
However, surprisingly, in contrast to the upregulation of PD-L1
in cancer cells after DNA damage, the DNA damage-dependent upregulation of PD-L1 expression does not occur in primary normal human dermal fibroblasts. 22 Cultured primary fibroblasts usually have a greater G 1 population compared with cancer cells. As activation of the ATR/Chk1 pathway requires ssDNA-RPA formation, which specifically occurs in S/G 2 during the progression of HR, the activity of ATR/ Chk1 signaling after DNA damage might be insufficient to promote the expression of PD-L1 in primary fibroblasts. Alternatively, signaling through the STAT1/3-IRF1 pathway might not be effectively activated F I G U R E 2 Regulation of programmed death-ligand 1 (PD-L1) expression in the context of DNA damage-induced signaling in cancer cells. PD-L1 expression is differentially regulated by neoantigens, cyclic GMP-AMP synthase (cGAS)/ stimulator of interferon genes (STING), ataxia telangiectasia and Rad3 related (ATR)/checkpoint kinase (Chk1), and the damage-associated molecular pattern pathways in cancer cells. ATM, ataxiatelangiectasia mutated; DSB, doublestrand break; ER, endoplasmic reticulum; HR, homologous recombination; IFN, interferon; IFNAR, interferon alpha/ beta receptor; IFNGR, interferon gamma receptor; IRF, interferon regulatory factor because of negative epistatic regulation or through posttranslational modifications in the signal cascade.
In summary, ATM-ATR/Chk1-dependent upregulation of PD-L1 expression represents an early immune response in cancer cells that survive after DNA damage. Following DSB end resection during repair in G 2 cells, the signal generated by ATR/Chk1 is transmitted approximately 1-2 hours after IR, continuing for 24-48 hours. For example, 10 Gy X-rays activate ATR/Chk1 signaling to cause G 2 /M checkpoint arrest, which is maintained for 24-48 hours. Because the output of the G 1 /S checkpoint machinery is generally downregulated in cancer cells (see above), the cells that accumulate in G 2 activate ATR/Chk1 signaling in the process of HR. Consistent with the timing of the accumulation of G 2 phase, the levels of PD-L1 mRNA increase 16 hours after IR. 3 Thus, DNA damage signal-dependent upregulation of PD-L1 expression on the cell surface occurs during an early time of the immune response against surviving cancer cells that are arrested at the G 2 /M cell cycle checkpoint.
| C Y TOSOLI C DNA FR AG MENTS AC TIVATE THE CG A S/S TING -MED IATED IFN PATHWAY AF TER DNA DAMAG E
In response to DSBs, cell cycle checkpoint arrest is induced by ATMand ATR/Chk1-dependent signaling. Damaged cells are arrested at each phase of the cell cycle through the checkpoint machinery such as the G 1 /S, intra-S, and G 2 /M checkpoints. For example, the G 2 /M checkpoint plays a critical role in preventing genome instability by suppressing the transition of the cell cycle toward M phase. 6 However, the G 2 /M checkpoint cannot sensitively monitor DSBs; that is, more than 10-20 DSBs are required to activate G 2 /M checkpoint arrest. 8, 23 Such insensitive checkpoint monitoring can occur in normal human cells, and generally, the sensitivity decreases in cancer cells, that is, DNA-damaged cancer cells progress into M phase with a greater number of DSBs compared to normal cells. 10 (Figure 2) . 25, 26 The notion that the cGAS/STING pathway is involved in the immune response within the tumor environment is supported by the finding that a specific Chk1 inhibitor used in clinical trials upregulates cGAS/STING signaling subsequent to the formation of micronuclei, possibly due to defective G 2 /M checkpoint arrest. 27 Micronuclei-induced cGAS/STING signaling under Chk1 inhibition stimulates the immune response, including PD-L1 expression. 27 Poly (ADP-ribose) polymerase promotes SSB repair and BER by recruiting the required repair proteins. 28 Poly (ADP-ribose) polymerase inhibitor traps PARP1/2 on damaged DNA, which causes DNA replication stress in S phase. The presence of such lesions involving trapped PARP1/2 places a reliance on HR and such lesions are enhanced in HR-defective cancer cells. The treatment of PARPi upregulates PD-L1 expression in breast cancer cell lines. 29 One of the mechanisms upregulating PD-L1 following PARPi treatment is thought to be dependent on the inactivation of glycogen synthase kinase 3β, which results in PD-L1 stabilization. 29, 30 In addition to the mechanisms above, recent studies reported that clinical PARPi potentiates an antitumor effect due to the upregulation of PD-L1 expression and the enhancement of cytotoxic T cell infiltration. 31, 32 In these reports, the authors suggest that PARPiinduced PD-L1 upregulation is considered to be due to the cGAS/ STING-dependent immune activation following the increase in the formation of micronuclei. The DNA damage-induced micronuclei are formed when mitotic cells contain unrepaired DNA or chromosomal translocations, and particularly the formation of micronuclei is enhanced in cells treated with PARPi or in cells defective in HR, such as BRCA1-deficient cancer cells. 31, 32 Such DNA damage-induced micronuclei could effectively elicit the cGAS/STING-dependent immune activation, followed by the upregulation of PD-L1 in cancer cells. In contrast, another study identified an alternative pathway suggesting that ATM activates STING signaling in nuclei independent of cGAS after DNA damage. 33 Thus, several distinct signaling pathways required for immune activation following DNA damage have been intensively investigated. In addition, from the clinical point of view, cGAS/STING-dependent immune activation is considered to be involved in promoting the abscopal effect (a systemic antitumor response distant from the X-ray-irradiated tumors). 25 The ATR/Chk1-dependent upregulation of PD-L1 expression occurs during G 2 /M checkpoint arrest, that is, at an early time after DNA damage. However, we propose that the cGAS/STING-dependent immune response is induced at the mid-phase of the immune response after DNA damage because micronuclei are generated following the release of cells from G 2 /M checkpoint arrest.
| AN IMMUNE RE S P ON S E MED IATED BY CELL DE ATH S I G NAL AF TER DNA DAMAG E
In the tumor environment, signals generated by dying cells stimulate the immune response to the surrounding viable cancer cells after DNA damage. After radiotherapy and chemotherapy, when cancer cells incur excessive DNA damage, cells undergo apoptosis or mitotic catastrophe-mediated cell death. The signals from dying or dead cells are generated by DAMP molecules that upregulate immune signaling in the tumor environment. High mobility group box-1, which binds to histones to modulate chromatin structure, is released during cell death. Released HMGB1 from dying cells activates the TLR4 pathway to increase MyD88/TRIF signaling. 34 Thereafter, the HMGB1-mediated TLR4/MyD88/TRIF pathway stimulates immune activity. Such cell death releasing DAMPs is called immunogenic cell death. 35 While DAMPs stimulate immune activity, leading to further cancer cell-killing, HMGB1-mediated TLR4/MyD88/TRIF signaling upregulates PD-L1 expression in surrounding viable cancer cells. 36 Consistent with this finding, there is a positive correlation between TLR4 and PD-L1 expression in tumors. 37 In addition, elevated TLR4 expression is associated with poor survival of cancer patients. 37 show better therapeutic outcomes after radiotherapy that might promote the release of DAMPs subsequent to radiotherapy. 38 In contrast, it is well known that the activity of the HR pathway is downregulated in certain tumors. 39 Such DAMPs could cause further immune-mediated cell death in the surrounding tumors due to DSB repair deficiency. Hence, we also propose that patients with insufficient DSB repair activity should be considered candidates to receive anti-PD-1/PD-L1 therapy, particularly combined with radiotherapy, chemotherapy, or both. 40 
| REG UL ATI ON OF PD -L1 E X PR E S S I O N IN TUMOR S IN THE CONTE X T OF MUTATI ONAL BURDEN , MI CROSATELLITE IN S TAB ILIT Y, AND DNA REPAIR
Cancer cells evade the immune system through the acquisition of immunoresistance. 41 During tumorigenesis, the upregulation of PD-L1 expression in tumor cells could contribute to immunoresistance. Expression of PD-L1 in tumor cells is regulated by IFNs, which are mainly classified as type I (IFNα and IFNβ) and type II (IFNγ).
Particularly, the signaling stimulated by IFNγ induces the upregulation of PD-L1 expression, which is stronger and more continuous compared with the stimuli generated by IFNα and IFNβ. 20 Activated T cells, in response to IFN stimuli, upregulate JAK1/2-STAT1/3 signaling. 20 Phosphorylated STAT1/3, generated through IFN-dependent signaling, induces upregulation of IRF1 expression. 21 The transcriptional activator IRF1 binds to the promoter region of PD-L1 to induce transcription.
The total mutational level (also known as TMB) is considered an effective biomarker for anti-PD-1/PD-L1 therapy, because high TMB should confer abnormal protein production caused by mutational changes such as deletion/insertion-dependent frameshifts in the ORF of a gene. Such abnormal proteins are recognized and degraded by proteasomes, generating peptides. Some such peptides (neoantigens) are presented on the cell surface as an HLA-neoantigen complex (Figure 2) . The HLA-neoantigen complex is recognized by the T-cell receptor, which activates T cells.
Activated T cells release IFNs into the tumor microenvironment.
The released IFNs are internalized by other tumor cells through the IFN receptors and activate signaling through the STAT1/3-IRF1 pathway (as described above), leading to immune stimulation, including the upregulation of PD-L1 expression in the tumor cells ( Figure 2 ). 21 Thus, mutated proteins are supposed to mediate the upregulation of PD-L1 expression and could contribute to the establishment of an immunosuppressive environment. Therefore, a model for neoantigen-dependent T cell activation proposes a relationship between TMB and the efficacy of anti-PD-1/PD-L1 therapy. 42 Interestingly, a recent study showed that, despite tumor heterogeneity, clonal neoantigens preferentially elicit T cell immunoreactivity. 43 Although the local TMB could cause local neoantigen production, current knowledge provides a notion that clonal neoantigen effectively promotes neoantigen-reactive T cells.
Thus, neoantigen heterogeneity could influence the efficacy of immune checkpoint therapy.
F I G U R E 4 Chronology of the regulation of immune reactions induced by DNA damage-dependent cellular responses. After DNA damage, cell cycle progression is arrested at the G 2 /M checkpoint. For example, 48-72 h after exposure to 10-Gy X-rays, G 2 /M checkpoint arrest is released and G 2 cells progress into M phase with double-strand breaks, followed by the formation of micronuclei in the next G 1 . Finally, cancer cells receive a lethal dose of DNA damage. The upregulation of programmed death-ligand 1 (PD-L1) expression is induced in each process, although through distinct molecular mechanisms. Thus, anti-PD-1/PD-L1 therapy could be given when the upregulation of PD-L1 expression is induced under conditions of symmetrically stimulated immune activation. ATR, ataxia telangiectasia and Rad3 related; cGAS, cyclic GMP-AMP synthase; Chk1, checkpoint kinase 1; DAMP, damage-associated molecular pattern; DC, dendritic cell; HLA, human leukocyte antigen; IFN, interferon; IRF, interferon regulatory factor; STING, stimulator of interferon genes Alternatively, accumulating reports have shown that the rate of MSI correlates strongly with the efficacy of anti-PD-1/PD-L1 therapy. 44 Therefore, MSI is considered a more promising marker to assess the effectiveness of anti-PD-1/PD-L1 therapy. A microsatellite is a tract of a few base pairs of a DNA sequence repeated 5-50 times.
Although the number of microsatellite sequences can change during DNA replication, MMR is able to correct not only mispaired bases but also insertions and deletions; therefore, lack of MMR activity causes aberrations in microsatellite repeats, resulting in an increase in genome-wide MSI. Interestingly, tumors with mutations in BER genes also show a high frequency of MSI, and BER-deficient tumors express higher levels of neoantigens and PD-L1. 14 Accumulating evidence shows that tumor cells with defective MMR show greater antitumor activity following anti-PD-1/PD-L1 treatments, which improves long-term survival. 45, 46 Therefore, MSI is considered a better therapeutic marker for anti-PD-1/PD-L1 cancer therapy than TMB. Although the choice between MSI and TMB as a biomarker for anti-PD/PD-L1 therapy has not been elucidated at a molecular level, MSI has an advantage in terms of cost and convenience for examination. Currently, single-base microsatellite sequences are used as a marker to assess the efficacy of anti-PD-1/ PD-L1 therapy. Such single-base microsatellite sequences could be distributed throughout the human genome, possibly in gene bodies, although the number of repeats is less than those of other representative microsatellite sequences.
In summary, accumulating evidence shows that tumors with a high mutational burden and MSI, which confers constitutive upregulation of PD-L1 expression, are predicted to display sensitivity to anti-PD-1/PD-L1 therapy. Thus, at present, the use of MSI is a reasonable choice as the most effective marker predicting the response to PD-1/PD-L1 blockade. However, as microsatellite repeats might not always correlate with the production of neoantigens, further studies are required to precisely identify the links between MSI, neoantigens, and the therapeutic effect of the PD-1/PD-L1 blockade, to further optimize MSI as a marker.
| SUMMARY AND PER S PEC TIVE S
The highly encouraging results published in 2015 of anti-PD-1 Ab therapy given to patients with advanced melanoma and non-small cell lung carcinoma, were followed by reports of successful PD-1/ PD-L1 therapy of patients with other cancers. [47] [48] [49] Furthermore, clinical and preclinical studies indicate that the combination of anti-PD-1/PD-L1 Ab with conventional cancer therapies, such as radiotherapy and chemotherapy, could be, at least in some cases, even more effective. 50, 51 However, our knowledge of the underlying molecular mechanism is insufficient and hinders development of the optimal treatment to achieve precision medicine.
If the chronology of the regulation of PD-L1 expression caused by DNA damage is considered, 4 steps can be proposed (Figure 4 , 
